Fed Circuit Watch: Treatment Method Claims Found Patent-Eligible

101 fed circuit watch patent patent eligible subject matter

The third treatment method case in the last year that was challenged as patent-ineligible subject matter under 35 U.S.C. §101 has been found eligible by the Court of Appeals for the Federal Circuit, in a recent case, Endo Pharms. Inc. v. Teva Pharms. USA, Inc.,[1] decided March 28, 2019. Endo owns U.S. Patent No. 8,808,737 …

Continue Reading

Fed Circuit Watch: Cat’s Out of the Bag: Continuous Reduction to Practice is Reasonable Diligence

102 fed circuit watch patent reduction to practice

Arctic Cat Inc. has been involved in a few patent-related cases in recent years, including one case from 2018 which we discussed on this blog dealing with the law of obviousness’s motivation to combine analysis under 35 U.S.C. §103.  Its most recent foray into the Court of Appeals for the Federal Circuit resulted in its …

Continue Reading

CannabIP: U.S. Patent No. 10,206,963 B2

Cannabis IP patent

U.S. Patent No. 10,206,963 B2 (‘963) issued on January 15, 2019, for “Topical Medicinal Gel.”  It was issued to applicants/inventors Joan McMahon of Midland, Michigan and Stephanie House of Merrill, Michigan.  The ‘963 patent discloses a process for a topical composition containing cannabis.  The novel aspect is rather than containing a greasy emollient like olive …

Continue Reading

TechPat: U.S. Patent No. D842,331 S1

patent Tech Patents technology

U.S. Patent No. D842,331 S (‘331) issued on March 5, 2019, for “Display Screen or Portion Thereof with Animated Graphical User Interface.”  It was issued to inventors Jisi Guo, Eli Guerron, Craig Dehner, Frank Yoo, Karina van Schaardenburg, and Hernrique Penha, all of San Francisco, California.  The applicant/assignee is Lyft, Inc. of San Francisco, California, …

Continue Reading

TechPat: U.S. Patent No. 10,190,137 B2

patent Tech Patents

An earlier posting on this blog discussed the recent issuance of a U.C.-researched CRISPR patent.  Today’s posting discusses a competing team’s recent issuance of another CRISPR patent. U.S. Patent No. 10,190,137 B2 (‘137) issued on January 29, 2019, for “CRISPR-Related Methods and Compositions with Governing gRNAs.”  It was issued to inventors Feng Zhang of Cambridge, …

Continue Reading

CannabIP: District Court Finds §101 Patent-Eligibility in First Cannabis Patent Litigation

101 Cannabis IP patent patent eligible subject matter

On April 17, 2019, Judge William J. Martinez denied an early motion for partial summary judgment for invalidity based patent-ineligible subject matter under 35 U.S.C. §101, in the first federal patent infringement case testing the patent claims of cannabinoid formulations.  Judge Martinez, sitting in the District of Colorado, found the patent-at-issue, U.S. Patent No. 9,730,911 …

Continue Reading

Fed Circuit Watch: Network Intrusion Claims Found Patent-Eligible

101 fed circuit watch patent patent eligible subject matter

On March 20, 2019, the Court of Appeals for the Federal Circuit ruled in SRI Int’l, Inc. v. Cisco Sys., Inc.,[1] in which claims directed to network intrusion were found patent-eligible under 35 U.S.C. §101.  While the ruling is a welcome sign of patent-eligibility, the ruling itself is convoluted in its rationale and difficult to …

Continue Reading